The versatile multibiomarker disease activity (MBDA) score may be able to predict rheumatoid arthritis (RA) relapse within the first year of tapering disease-modifying antirheumatic drug (DMARD) treatment.
Data presented in poster format at the 2015 annual meeting of the American College of Rheumatology1 and also published in the Annals of the Rheumatic Diseases2 indicated 58% of patients who relapsed had moderate or high MBDA scores at baseline versus 21% of those who remained in remission.
The analysis was based on outcomes in RETRO, a phase 3, multicenter, randomized, open-label, prospective, controlled, parallel-group study. The patients, who had been in remission for at least 6 months, were randomized to continuation of their existing conventional or biologic DMARD for 1 year, 50% reduction of the DMARD over 1 year, or 50% reduction of the DMARD over the first 6 months before complete cessation of the DMARD.
A multivariate logistic regression analysis indicated that being positive for anticitrullinated protein antibody was a predictor of relapse (OR = 24.47), as were elevated MBDA score (odds ratio [OR] = 8.54), DMARD continuation versus tapering (OR = 5.94), and DMARD continuation versus stopping (OR = 5.41).
- Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multi-biomarker disease activity (MBDA) and autoantibody status in rheumatoid arthritis patients tapering DMARD treatment. Presented at: 2015 American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA. Abstract 2584.
- Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2015 Oct 19. Epub ahead of print.